Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Key Tips for Buying COVID Vaccine Stocks

By Keith Speights - Nov 23, 2020 at 8:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One principle is especially important.

The market for coronavirus vaccines will be enormous. That presents great opportunities for investors. But how should you move forward with going after those opportunities? In this Motley Fool Live video recorded on Nov. 16, 2020, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com writer Keith Speights talk about key tips for investing in COVID vaccine stocks.

Corinne Cardina: Let's wrap up with something general for investors. Keith, what tips do you have for investors who might be thinking about buying stocks in the coronavirus vaccine landscape today? Are there any strategies that might be market beaters?

Keith Speights: First of all, I would say, "know thy own self." The old proverb there. Understand your own risk tolerance. If you're averse to risk, you're not going to want to jump on some of these smaller biotech stocks that don't have other proven candidates or other proven drugs on the market.

But I've mentioned Novavax ( NVAX -0.92% ). Novavax is one of those high-risk, high-reward-type stocks that if things go well, that stock could really take off. When I say take off, it wouldn't shock me for Novavax to shoot up 4 or 5 times. They're around $6 billion in market cap now. Compare that to say BioNTech ( BNTX 3.17% ) or Moderna ( MRNA 1.74% ) that are in the $20 and $30 billion range, so Novavax could be a huge winner if things go well. If their vaccine isn't successful, that stock is going to go down. That's one that I would really watch.

But I would also throw in some of these big ones. Pfizer ( PFE 2.32% ) has a lot of good things going forward. AstraZeneca ( AZN -1.02% ) has a lot of good things going forward other than their COVID-19 program. There other reasons to buy these stocks rather than just their coronavirus vaccines.

Corinne Cardina: That's a great point, and don't put all your eggs in one basket. It's important to make sure if you are investing in coronavirus vaccine stocks, dedicate a specific percentage and stick to what you plan. Don't get carried away and just start buying on every good news.

Speaking of Novavax, do we know when Novavax plans to release any data about the trial that they're currently in?

Keith Speights: I do know that they plan to release the U.K. phase three data early next year. They haven't been more specific than that. That's the latest that I've seen.

Corinne Cardina: Okay, cool. Novavax, are they waiting on a decision about their flu vaccine? Where are they on the flu vaccine?

Keith Speights: They have a very promising flu vaccine called NanoFlu. Basically, they've set up a team to advance the regulatory filing process for that vaccine. They do have to do a lot consistency trial first. They haven't set a date, but if I had to guess, I would say that sometime in 2021 they would be at a point where they could file for approval for that vaccine, and not emergency use authorization in that case, full FDA approval. Novavax has also said that they are exploring the possibility of combining their flu vaccine with their COVID-19 vaccine, which would be quite promising if they're able to do that.

Corinne Cardina: Wow, that is amazing, especially for those of us who don't love to pricked by needles.

Keith Speights: Exactly.

Corinne Cardina: You could do it all in one shot. Amazing. Awesome. Well, thank you so much, Keith. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$54.27 (2.32%) $1.23
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.23 (-1.02%) $0.56
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$160.48 (-0.92%) $-1.49
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$306.72 (1.74%) $5.23
BioNTech SE Stock Quote
BioNTech SE
BNTX
$344.06 (3.17%) $10.57

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
640%
 
S&P 500 Returns
139%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.